Skip to main content
SpringerLink
Log in

Diagnosis and Management of Epithelial Ovarian Cancer

  • Reference work entry
  • First Online:
Handbook of Gynecology

  • 435 Accesses

Abstract

Ovarian cancer is the fifth most common cancer among women after breast, bowel, lung, and endometrial and remains the leading cause of death due to gynecological malignancy (Cancer.org 2021). Epithelial ovarian cancer accounts for the vast majority of ovarian malignancies with figures of around 85%. Due to its insidious nature of presentation, it is often not diagnosed until the later stages leading to a high mortality rate. Five-year survival is very much influenced by stage at diagnosis. Over the last 25 years, incidence and mortality have remained fairly static, and much research is being undertaken looking for aids to diagnosis, possible screening methods, and improvement in treatment options, both surgical and medical. In this chapter we will discuss presentation, diagnostic tools, and possible management regimens for patients with epithelial ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 999.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Banerjee S, Gonzalez-Martin A, Harter P, Lorusso D, Moore KN, Oaknin A, Ray-Coquard I. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open – Cancer Horizons round-table discussion. ESMO Open. 2020;5(6):e001110. https://doi.org/10.1136/esmoopen-2020-001110. PMID: 33310779; PMCID: PMC7783599.

    Article  PubMed  PubMed Central  Google Scholar 

  • Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C. Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome. Eur J Cancer. 2012;48(5):687–94. Epub 2011 Jul 13

    Article  PubMed  Google Scholar 

  • Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.

    Article  PubMed  Google Scholar 

  • Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta- analysis. Gynecol Oncol. 2009;112(1):265–74.

    Article  PubMed  Google Scholar 

  • Cancerresearchuk (2021) https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovariancancer#heading-Three.

  • Chan K, Urban R, Hu JM, Shin JY, Husain A, Teng NN, Berek JS, Osann K, Kapp DS. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13 918 patients. Br J Cancer. 2007;96:1817–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19:4059–67.

    Article  PubMed  Google Scholar 

  • Clamp AR, James EC, McNeish IA, Dean A, Kim J-W, O’Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394:P2084–95.

    Article  Google Scholar 

  • Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929–39. https://doi.org/10.1056/NEJMoa1902626. PMID: 31722153; PMCID: PMC6941470.

    Article  PubMed  PubMed Central  Google Scholar 

  • Colombo PE, Mourregot A, Fabbro M, et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol. 2009;35(2):135–43.

    Article  PubMed  Google Scholar 

  • De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, Cacciari N, Al-Nahhas A, Rubello D, Venturoli S, Fanti S. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol. 2011;80(2):e98–103. Epub 2010 Aug 4

    Article  PubMed  Google Scholar 

  • Doufekas K, Olaitan A. Clinical epidemiology of epithelial ovarian cancer in the UK. Int J Women’s Health. 2014;6:537–45.

    Google Scholar 

  • du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115(6):1234–44.

    Article  PubMed  Google Scholar 

  • du Bois A, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Jensen PT, Selle F, Guyon F, Pomel C, Lecuru F, Zang R, Avall-Lundqvist E, Kim J-W, Ponce J, Raspagliesi F, Ghaem-Maghami S, Reinthaller A, Harter P. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. 2020;38(Suppl 15):6000.

    Article  Google Scholar 

  • Eisenkop SM, Spirtos NM, Montag TW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47:203–9.

    Article  CAS  PubMed  Google Scholar 

  • Fotopoulou C. How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort. J Gynecol Oncol. 2020;31(1):e26. https://doi.org/10.3802/jgo.2020.31.e26. Epub 2019 Nov 1. PMID: 31789002; PMCID: PMC6918883.

    Article  PubMed  Google Scholar 

  • Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J. Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol. 2010;36(12):1202–10. Epub 2010 Sep 22

    Article  CAS  PubMed  Google Scholar 

  • Fotopoulou C, Richter R, Braicu IE, et al. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol. 2011;18:49–57.

    Article  PubMed  Google Scholar 

  • Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol. 2013a;20(4):1348–54. Epub 2012 Oct 2

    Article  PubMed  Google Scholar 

  • Fotopoulou C, Savvatis K, Kosian P, Braicu IE, Papanikolaou G, Pietzner K, Schmidt SC, Sehouli J. Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter? Br J Cancer. 2013b;108(1):32–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021;22(5):632–42. https://doi.org/10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13. PMID: 33862001

    Article  CAS  PubMed  Google Scholar 

  • Gabra H. Back to the future: targeting molecular changes for platinum resistance reversal. Gynecol Oncol. 2010;118:210–1.

    Article  PubMed  Google Scholar 

  • Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012;55(1):36–42.

    Article  PubMed  Google Scholar 

  • Gultekin M, Velipaşaoğlu M, Aksan G, Dursun P, Dogan NU, Yuce K, Ayhan A. A third evaluation of tertiary cytoreduction. J Surg Oncol. 2008;98(7):530–4.

    Article  PubMed  Google Scholar 

  • Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J. Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.

    Article  PubMed  Google Scholar 

  • Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, du Bois A. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(5):1324–30.

    Article  CAS  PubMed  Google Scholar 

  • Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289–95.

    Article  PubMed  Google Scholar 

  • Helm CW, Chief Editor: Harris JE. Ovarian cancer staging. 2014. http://emedicine.medscape.com/article/2007140-overview

  • Hızlı D, Boran N, Yılmaz S, Turan T, Altınbaş SK, Celik B, Köse MF. Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2012;163(1):71–5.

    Article  PubMed  Google Scholar 

  • Inci MG, Anders L, Woopen H, Richter R, Guzel D, Armbrust R, Sehouli J. Frailty index for prediction of surgical outcome in ovarian cancer: results of a prospective study. Gynecol Oncol. 2021;161(2):396–401. https://doi.org/10.1016/j.ygyno.2021.02.012. Epub 2021 Feb 16. PMID: 33608143.

    Article  PubMed  Google Scholar 

  • Janczar S, Graham JS, Paige AJW, Gabra H. Targeting locoregional peritoneal dissemination in ovarian cancer. Expert Rev Obstet Gynecol. 2009;4(2):133–47.

    Article  Google Scholar 

  • Jemal A, et al. Cancer statistics. Cancer J Clin. 2007;57(1):43–66.

    Article  Google Scholar 

  • Karam AK, Santillan A, Bristow RE, Giuntoli R 2nd, Gardner GJ, Cass I, Karlan BY, Li AJ. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol. 2007;104(2):377–80. Epub 2006 Oct 2

    Article  PubMed  Google Scholar 

  • Kehoe S, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.

    Article  PubMed  Google Scholar 

  • Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of Niraparib in combination with Pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141–9. https://doi.org/10.1001/jamaoncol.2019.1048.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer – a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–43.

    Article  PubMed  PubMed Central  Google Scholar 

  • Leitao MM Jr, Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2004;95:181–8.

    Article  PubMed  Google Scholar 

  • Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer. 2009;19(Suppl 2):S63–7. https://doi.org/10.1111/IGC.0b013e3181c104fa.

    Article  PubMed  Google Scholar 

  • Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecol Oncol. 1989;33(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  • NICE (2011) http://www.nice.org.uk/guidance/CG122/chapter/Appendix-D-Risk-of-malignancy-index-RMI-I.

  • Omura G, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986;57:1725–30.

    Article  CAS  PubMed  Google Scholar 

  • Paulsen T, Kjaerheim K, Kaern J, et al. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16(Suppl 1):11–7.

    Article  PubMed  Google Scholar 

  • Petrillo M, Ferrandina G, Fagotti A, Vizzielli G, Margariti PA, Pedone AL, Nero C, Fanfani F, Scambia G. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol. 2013;20(12):3955–60.

    Article  CAS  PubMed  Google Scholar 

  • Pignata S, Scambia G, Raspagliesi F, Murgia V, Pisano C, Salutari V, Bologna A, Sorio R, Ferrandina G, Sacco C, Vergote I, Cormio G, Breda E, Cinieri S, Cecere SC, Wagner UAG, Daniele G, Gallo C, Perrone F, Piccirillo MC. The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG. J Clin Oncol. 2016;34(suppl 15):5505. https://doi.org/10.1200/JCO.2016.34.15_suppl.5505.

    Article  Google Scholar 

  • Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Pisano C, Selle F, Zaccarelli E, Scambia G, Pautier P, Nicoletto MO, De Giorgi U, Dubot C, Bologna A, Orditura M, Ray-Coquard IL, Perrone F, Daniele G, On the behalf of MITO, GINECO, MaNGO, SAKK and HeCOG groups. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol. 2018;36(Suppl 15):5506.

    Article  Google Scholar 

  • Ray-Coquard, P. Pautier, S. Pignata, D. Prol, A. Gonzlez-Martn, R. Berger, K. Fujiwara, I. Vergote, N. Colombo, J. Menp, F. Selle, J. Sehouli, D. Lorusso, E.M. Guerra Ala, A. Reinthaller, S. Nagao, C. Lefeuvre-Plesse, U. Canzler, G. Scambia, A. Lortholary, F. Marm, P. Combe, N. de Gregorio, M. Rodrigues, P. Buderath, C. Dubot, A. Burges, B. You, E. Pujade-Lauraine, and P. Harter, for the PAOLA-1 Investigators*. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381:2416–2428. : https://doi.org/10.1056/NEJMoa1911361.

  • Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, Guyon F, Greggi S, Mosgaard BJ, Reinthaller A, Hilpert F, Schade-Brittinger C, Chi DS, Mahner S. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer. 2019;29(8):1327–31. https://doi.org/10.1136/ijgc-2019-000682. Epub 2019 Aug 15. PMID: 31420412

    Article  PubMed  Google Scholar 

  • Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 1993;11(3):434–9.

    Article  CAS  PubMed  Google Scholar 

  • Sehouli J, Papanikolaou G, Braicu EI, Pietzner K, Neuhaus P, Fotopoulou C. Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer. Ann Surg Oncol. 2012;19(4):1326–33.

    Article  PubMed  Google Scholar 

  • Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439–49. https://doi.org/10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8

    Article  CAS  PubMed  Google Scholar 

  • Shih KK, Chi DS, Barakat RR, Leitao MM Jr. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol. 2010a;117:330–5.

    Article  CAS  PubMed  Google Scholar 

  • Shih KK, Chi DS, Barakat RR, Leitao MM Jr. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2010b;116(3):364–9. Epub 2009 Nov 7

    Article  CAS  PubMed  Google Scholar 

  • Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19(2):597–604.

    Article  PubMed  Google Scholar 

  • Timmerman D. et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839.

    Google Scholar 

  • Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vergote I, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  CAS  PubMed  Google Scholar 

  • Vernooij F, Heintz P, Witteveen E, et al. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol. 2007;105:801–12.

    Article  PubMed  Google Scholar 

  • Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105(7):890–6. Epub 2011 Aug 30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • WHO (2014) http://www.who.int/selection_medicines/committees/expert/20/applications/EpithelialOvarian.pdf?ua=1.

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology, Imperial College NHS Trust, Queen Charlottes and Hammersmith Hospital, London, UK

    Katherine Nixon

  2. Department of Gynaecological Oncology, West London Gynecological Cancer Centre, Imperial College NHS Trust, Queen Charlottes and Hammersmith Hospital, London, UK

    Christina Fotopoulou

Authors
  1. Katherine Nixon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Fotopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Donna Shoupe

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nixon, K., Fotopoulou, C. (2023). Diagnosis and Management of Epithelial Ovarian Cancer. In: Shoupe, D. (eds) Handbook of Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-031-14881-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14881-1_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14880-4

  • Online ISBN: 978-3-031-14881-1

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation